23 results
IDSA Recommendations for Treating Visceral and Cutaneous Leishmaniasis in HIV-AIDS
Treating Visceral Leishmaniasis - Preferred Therapy:
 •
IDSA Recommendations ... mg/kg on days 1– ... and CD4 count < ... #Prevention #Treatment ... infections #HIVAIDS #pharmacology
Leishmaniasis Life Cycle
1) Sandfly takes a blood meal (injects promastigote stage into the skin)
Human Stages:
2) Promastigotes
Leishmaniasis Life ... Cycle 1) Sandfly ... LifeCycle #diagnosis #pathophysiology ... #infectiousdiseases ... #cdc #parasite
IDSA Recommendations for Preventing and Treating Penicillium marneffei Infections in HIV-AIDS
Preventing 1st Episode of Penicilliosis (Primary
IDSA Recommendations ... for Preventing ... Penicilliosis #IDSA ... #Prevention #Treatment ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Preventing and Treating Toxoplasma gondii Encephalitis in HIV-AIDS
Indications for Initiating Primary Prophylaxis:
 •
IDSA Recommendations ... for Preventing ... patients with CD4 ... #Prevention #Treatment ... #pharmacology
C.diff - Clostridioides Difficile Infection (CDI) - Diagnosis and Management - GrepMed Handbook

Clinical Presentation + Progression:
Perforation) Pathophysiology ... Epidemiology: • #1 ... 10 mg/kg IV x 1 ... IDSA 2021 CDI ... #infectiousdiseases
IDSA Recommendations for Preventing Human Papillomavirus Infections and Cervical Cancer Screening for Women with in HIV-AIDS
Recommendations
IDSA Recommendations ... screen within 1 ... 0.5mL IM at 0, 1– ... #Prevention #Treatment ... infections #HIVAIDS #pharmacology
Visceral Leishmaniasis - Diagnosis and Management Summary
Species: Leishmania donovani, Leishmania infantum, Leishmania chagasi
Where: South Asia, East
Visceral Leishmaniasis ... antigen-specific CD4 ... : 1) Liposomal ... mg/kg on days 1- ... #infectiousdiseases
IDSA Recommendations for Preventing and Treating Bacterial Enteric Infections in HIV-AIDS
Preventing Bacterial Enteric Illness:
 • Antimicrobial
IDSA Recommendations ... difficile Infection (CDI ... Enteric #Bacterial #IDSA ... #Prevention #Treatment ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Treating Mucosal Candidiasis in HIV-AIDS
Oropharyngeal Candidiasis: Initial Episodes (Duration of Therapy: 7–14 days)
Preferred
IDSA Recommendations ... 4–6 mL QID or 1– ... candida #mucosal #IDSA ... #Prevention #Treatment ... infections #HIVAIDS #pharmacology
IDSA Recommendations for Prevention and Treatment of Pneumocystis Pneumonia (PCP) in HIV-AIDS
Indications for Initiating Primary Prophylaxis:
IDSA Recommendations ... for Prevention ... and Treatment of ... #Prevention #Treatment ... HIVAIDS #management #pharmacology